For
UK
audiences
The essential guide to product selection
The essential guide to product selection
Immunosuppressant
Moderately to severely active UC in adults
Hypersensitivity to the active substance or to any of the excipients; immunodeficient state predisposing to systemic opportunistic infections; patients who in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischaemic attack decompensated heart failure requiring hospitalisation or New York Heart Association Class III/IV heart failure; patients with history or presence of second-degree atrioventricular block type ii or third-degree AV block or sick sinus syndrome unless the patient has a functioning pacemaker; severe active infections, active chronic infections such as hepatitis and tuberculosis; active malignancies; severe hepatic impairment; during pregnancy and in women of childbearing potential not using effective contraception.
Oral capsule
Dose: Initially 0.23mg once daily on days 1–4, then increased to 0.46 mg once daily on days 5–7, then increased to 0.92 mg once daily from day 8
0.23mg capsules (4), £CS; 0.46mg (3), £CS; 0.92mg (28), £1,373.00
£CS-£1373.00